ATE129254T1 - Antientzündungsmittel und zusammensetzungen. - Google Patents

Antientzündungsmittel und zusammensetzungen.

Info

Publication number
ATE129254T1
ATE129254T1 AT88902773T AT88902773T ATE129254T1 AT E129254 T1 ATE129254 T1 AT E129254T1 AT 88902773 T AT88902773 T AT 88902773T AT 88902773 T AT88902773 T AT 88902773T AT E129254 T1 ATE129254 T1 AT E129254T1
Authority
AT
Austria
Prior art keywords
compositions
inflammatory agents
polysulfate
xylan
derivatives
Prior art date
Application number
AT88902773T
Other languages
English (en)
Inventor
David Cullis-Hill
Peter Ghosh
Original Assignee
Arthropharm Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthropharm Pty Ltd filed Critical Arthropharm Pty Ltd
Application granted granted Critical
Publication of ATE129254T1 publication Critical patent/ATE129254T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0057—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT88902773T 1987-03-19 1988-03-21 Antientzündungsmittel und zusammensetzungen. ATE129254T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPI095187 1987-03-19
AUPI247887 1987-06-15
AUPI581987 1987-12-09

Publications (1)

Publication Number Publication Date
ATE129254T1 true ATE129254T1 (de) 1995-11-15

Family

ID=27157350

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88902773T ATE129254T1 (de) 1987-03-19 1988-03-21 Antientzündungsmittel und zusammensetzungen.

Country Status (8)

Country Link
US (2) US5145841A (de)
EP (1) EP0356435B1 (de)
JP (1) JP2511829B2 (de)
AT (1) ATE129254T1 (de)
AU (1) AU604542B2 (de)
CA (1) CA1327354C (de)
DE (1) DE3854604T2 (de)
WO (1) WO1988007060A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85145A (en) * 1987-01-23 1994-08-26 Univ Australian Anti-metastatic pharmacological or veterinary preparations containing modified herpin with reduced anticoagulant activity
US4931553A (en) * 1988-05-11 1990-06-05 Gill Devinder S Platinum-polymer complexes and their use as antitumor agents
US5043438B1 (en) * 1989-02-16 1998-04-28 Lever Brothers Ltd Process for the synthesis of polyol fatty-acid esters
HU203372B (en) * 1989-02-24 1991-07-29 Richter Gedeon Vegyeszet Process for producing hyaluronic associates and pharmaceutical compositions and cosmetics comprising such active ingredient
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
JP2945993B2 (ja) * 1989-12-05 1999-09-06 武田薬品工業株式会社 外用剤
US5095037B1 (en) * 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
IT1240316B (it) * 1990-02-21 1993-12-07 Ricerca Di Schiena Del Dr. Michele G. Di Schiema & C. Composizioni a base di acido ialuronico ad alto peso molecolare somministrabili per via topica per il trattamento di infiammazioni del cavo orale ,per la cosmetica e l'igiene del cavo orale
IT1240744B (it) * 1990-04-05 1993-12-17 Bioindustria Spa Complessi di condroitinsolfato ad azione antiinfiammatoria
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
CA2061703C (en) * 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5990096A (en) * 1990-09-18 1999-11-23 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5639738A (en) * 1992-02-20 1997-06-17 Hyal Pharmaceutical Corporation Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5514667A (en) * 1990-11-05 1996-05-07 Arthropharm Pty. Limited Method for topical treatment of herpes infections
AU1162592A (en) * 1991-01-30 1992-09-07 Hoechst Aktiengesellschaft Low-molecular sulphated poly-beta -2,6-fructofuranosanes and their use in the treatment of degenerative articular ailments
WO1992013541A1 (de) * 1991-01-30 1992-08-20 Hoechst Aktiengesellschaft Die verwendung substituierter polysaccharide zur behandlung von degenerativen gelenkerkrankungen
AU1052492A (en) * 1991-01-31 1992-08-06 Farmitalia Carlo Erba S.R.L. Synergistic composition comprising a fibroblast growth factor and a sulfated polylsaccharide, for use as antiviral agent
US6103704A (en) * 1991-07-03 2000-08-15 Hyal Pharmaceutical Corporation Therapeutic methods using hyaluronic acid
US5977088A (en) * 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5990095A (en) * 1991-07-03 1999-11-23 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
US5817644A (en) * 1991-07-03 1998-10-06 Hyal Pharmaceutical Corporation Targeting of dosages of medicine and therapeutic agents
US6022866A (en) * 1991-07-03 2000-02-08 Hyal Pharmaceutical Corporation Use of hyaluronic acid and forms to prevent arterial restenosis
WO1994007505A1 (en) * 1991-07-03 1994-04-14 Norpharmco Inc. Use of hyaluronic acid and forms to prevent arterial restenosis
CA2061567C (en) * 1992-02-20 1998-02-03 Rudolf E. Falk Use of hyaluronic acid to repair ischemia reperfusion damage
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6218373B1 (en) 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5767106A (en) * 1992-02-21 1998-06-16 Hyal Pharmaceutical Corporation Treatment of disease and conditions associated with macrophage infiltration
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US5453444A (en) * 1992-10-13 1995-09-26 Otsuka Pharmaceutical Co., Ltd. Method to mitigate or eliminate weight loss
US5336620A (en) * 1993-01-27 1994-08-09 American Home Products Corporation Process for the production of an anticoagulant composition
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
DE69621528T2 (de) * 1995-02-07 2003-01-16 Shiseido Co. Ltd., Tokio/Tokyo Anti-inflamatorische agenzien
US6255091B1 (en) * 1995-04-28 2001-07-03 Axys Pharmaceuticals, Inc. Potentiating metal mediated serine protease inhibitors with cobalt or zinc ions
US6537977B1 (en) * 1995-09-19 2003-03-25 Seikagaku Corporation Anti-inflammatory agent
FR2740342B1 (fr) * 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques
US5861175A (en) * 1996-03-15 1999-01-19 Alliance Pharmaceutical Corp. Use of fluorocarbons for diagnosis and treatment of articular disorders
US5866554A (en) * 1996-07-19 1999-02-02 Shalaby; Shalaby W. Compositions for prevention of inflammation and adhesion formation and uses thereof
AUPO347396A0 (en) * 1996-11-04 1996-12-05 Medical Innovations Limited Synergistic gold-containing compositions
AU747169B2 (en) * 1996-11-04 2002-05-09 Psiron Limited Synergistic gold-containing compositions
US6255295B1 (en) * 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US7067144B2 (en) * 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
JP4607264B2 (ja) * 1998-12-01 2011-01-05 生化学工業株式会社 ヒアルロン酸を有効成分とする異所性石灰化抑制剤
JP2003089647A (ja) 1999-03-10 2003-03-28 Takada Seiyaku Kk 関節性疾患治療剤
FR2791262B1 (fr) 1999-03-22 2001-09-28 Virbac Sa Compositions a base de chondroitine et de chitosan pour la protection, le traitement ou le remplacement des tissus conjonctifs
US6608042B2 (en) * 2000-03-28 2003-08-19 Aventis Pharma, S.A. Pharmaceutical compositions containing oligosaccharides, the novel oligosaccharides and preparation thereof
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
DE10054257A1 (de) * 2000-11-02 2002-05-16 Kief Horst Heilmittel zur Intraarticulären Injektion
US6593310B1 (en) * 2000-11-21 2003-07-15 Arthropharm Pty. Ltd. Treatment of osteoporosis
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
ES2251289B1 (es) * 2004-02-27 2007-07-01 Bioiberica, S.A. Nuevo uso terapeutico de un grupo de polisacaridos sulfatados.
US20080214480A1 (en) * 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
WO2007123800A2 (en) * 2006-04-03 2007-11-01 Nutramax Laboratories, Inc. Stabilized pentosan polysulfate (pps) formulations and methods of analyzing them
EP1842545A1 (de) * 2006-04-04 2007-10-10 Marinomed Biotechnologie GmbH Entzündungshemmende Polymer
EP2007401A2 (de) * 2006-04-04 2008-12-31 Marinomed Biotechnologie GmbH Entzündungshemmendes polymer
US20080076723A1 (en) * 2006-09-27 2008-03-27 Sylvan Pharmaceuticals Pty Ltd. Inhibition of cathepsin K activity and the treatment and prevention of disease
AU2013234396B2 (en) * 2007-12-04 2014-09-11 Proteobioactives Pty Ltd Protection of progenitor cells and regulation of their differentiation
KR101718375B1 (ko) 2007-12-04 2017-03-22 프로테오바이오엑티브스 피티와이 엘티디 전구 세포의 보호 및 그의 분화 조절
AU2008100725B4 (en) * 2008-07-04 2008-10-02 Parnell Technologies Pty Ltd A sulfated polysaccharide compound for clinical use
WO2012027797A1 (en) * 2010-09-02 2012-03-08 David Charles James Anti-inflammatory compostion
WO2012114349A1 (en) * 2011-02-23 2012-08-30 Cadila Healthcare Limited An improved process for the preparation of pentosan polysulfate sodium
MX392702B (es) 2016-05-26 2025-03-24 Paradigm Biopharmaceuticals Ltd Sal sódica de polisulfato de pentosán para usarse en la reducción de dolor por inflamación inducida por virus del río ross, virus chikungunya y virus del bosque barmah en un individuo humano.
KR102075596B1 (ko) * 2017-12-04 2020-02-10 이일훈 덱스트란 또는 폴록사머를 포함하는 관절 질환 또는 결체조직 질환 치료용 조성물
WO2019157560A1 (en) 2018-02-16 2019-08-22 Proteobioactives Pty Limited Methods and compositions for the treatment of pain and/or inflammation
EP3791884A1 (de) 2019-09-16 2021-03-17 Oskar Bunz Kombination aus heparin und magnesiumsalz zur behandlung viraler infektionen
CN111001041B (zh) * 2019-12-10 2022-02-01 河南亚都实业有限公司 一种抗炎抗菌复合皮肤支架材料及制备方法
WO2021179047A1 (en) * 2020-03-12 2021-09-16 Cullis Hill Sydney David Treatment for coronavirus infection and associated cytokine toxicity

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1950100A (en) * 1932-06-02 1934-03-06 Jr Lathan A Crandall Chondroitin compounds and their preparation
GB603571A (en) * 1943-11-13 1948-06-18 Pharmacia Ab Compounds having a retarding action on the coagulation of blood and processes of preparing the same
US3275514A (en) * 1960-04-12 1966-09-27 Paul D Saltman Process for introduction of metals into the mammalian system
NL286444A (de) * 1961-12-08
JPS4713263Y1 (de) * 1966-07-29 1972-05-15
US3636202A (en) * 1968-02-12 1972-01-18 Lewis A Klein Treatment of rheumatoid arthritis and related diseases
JPS45156Y1 (de) * 1968-04-23 1970-01-07
US3719665A (en) * 1971-08-23 1973-03-06 Soc D Etudes Prod Chimique Chondroitin sulphuric acid salts
FR2177549B1 (de) * 1972-03-29 1975-04-25 Roussel Uclaf
GB1431047A (en) * 1972-05-09 1976-04-07 Gist Brocades Nv Packaging of materials
JPS4942486A (de) * 1972-08-29 1974-04-22
DD136572B1 (de) * 1977-10-06 1980-12-24 Horst Toepfer Verfahren zur herstellung eines therapeutisch wirksamen mukopolysaccaridpolyschwefelsaeureesters aus rinder-trachea
EP0012115A1 (de) * 1978-12-04 1980-06-11 Ciba-Geigy Ag Pharmazeutische Präparate zur topischen Behandlung von Virusinfektionen
BE885540A (fr) * 1979-10-05 1981-02-02 Biomed Res Inc Procede de preparation de sulfate de chrondroitine et composition pharmaceutique contenant ce dernier
US4302577A (en) * 1979-10-05 1981-11-24 Biomed Research Inc. Process for preparing CSA or CSC
AR224782A1 (es) * 1980-02-04 1982-01-15 Biomed Res Inc Procedimiento mejorado para la preparacion de sulfato de condroitina biologicamente"activo"de grado farmaceutico,predominantemente sulfato de condroitina a,sulfato de condroitina c y mezclas de los mismos
GB2080682B (en) * 1980-07-30 1984-03-28 Ciba Geigy Ag Antiherpetically active lipstick
DE3118588C2 (de) * 1981-05-11 1983-07-07 Luitpold-Werk, Chemisch-Pharmazeutische Fabrik, 8000 München Verfahren zur Herstellung eines injizierbaren hochreinen Chondroitinpolysulfates, hiernach erhältliches Produkt und pharmazeutische Zusammensetzung
US4510135A (en) * 1982-04-21 1985-04-09 Research Corporation Orally administered heparin
US4654327A (en) * 1982-04-21 1987-03-31 Research Corp. Quaternary ammonium complexes of heparin
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ZA838317B (en) * 1982-11-10 1984-06-27 Inco Res & Dev Center Inc Therapeutic compounds of platinum and palladium and their preparation
US4584392A (en) * 1982-11-10 1986-04-22 Inco Alloys International, Inc. Platinum and palladium complexes
DE3373782D1 (en) * 1982-12-20 1987-10-29 Harvard College Inhibition of angiogenesis
CA1218986A (en) * 1982-12-28 1987-03-10 Annamaria Naggi Process for the depolymerisation and sulfatation of polysaccharides
FR2538404B1 (de) * 1982-12-28 1985-08-23 Anic Spa
US4623539A (en) * 1983-02-04 1986-11-18 Tunc Deger C Nutrient barrier polysaccharide compositions and method of use
AU555747B2 (en) * 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
FR2553287B1 (fr) * 1983-10-18 1986-09-12 Choay Sa Compositions a base de mucopolysaccharides ou d'oligosaccharides, notamment a base de fractions ou fragments d'heparine, appropriees au traitement de desordres de la proliferation cellulaire
US4710493A (en) * 1984-08-14 1987-12-01 Albert Landsberger Therapeutic agent for the use in cancer treatment
FR2572731B1 (fr) * 1984-11-07 1987-03-06 Sanofi Sa Nouveaux sulfates de xylanes de bas poids moleculaires, leur procede de preparation et leur activite antithrombotique et hypolipemiante par voie orale
JPS61130301A (ja) * 1984-11-30 1986-06-18 Tokyo Univ 抗凝血活性を有する硫酸化キシロフラナン及びその製造法
US4582865A (en) * 1984-12-06 1986-04-15 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
EP0259485A4 (de) * 1986-03-14 1988-07-29 Bio Technology General Corp Schwermetallsalze von hyaluronsäure zur verwendung als antimikrobielles mittel.
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
AU600257B2 (en) * 1986-03-21 1990-08-09 International Pharmaceutical Products, Inc. Non-inflammatory hyaluronic acid fraction and process for preparing it
IT1189085B (it) * 1986-03-25 1988-01-28 Mediolanum Farmaceutici Srl Processo per la preparazione di dermatan solfato ad alta purezza e composizioni farmaceutiche che lo contengono
DE3782652D1 (de) * 1986-04-04 1992-12-17 Angiogenics Ltd Zubereitung zum stoppen von angiogenese und einem kapillar-, zellen- oder membranleck.
SE453394B (sv) * 1986-07-07 1988-02-01 Pharmacia Ab Forfarande for framstellning av sulfaterade polysackarider genom anvendning av ett reducerande medel for sulfateringsreaktionen
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
HU208029B (en) * 1988-06-03 1993-07-28 Italfarmaco Spa Process for producing glycose-amino-glycane salts and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
EP0356435A1 (de) 1990-03-07
JPH02502547A (ja) 1990-08-16
DE3854604D1 (de) 1995-11-23
EP0356435B1 (de) 1995-10-18
EP0356435A4 (de) 1990-06-26
US5470840A (en) 1995-11-28
JP2511829B2 (ja) 1996-07-03
WO1988007060A1 (en) 1988-09-22
US5145841A (en) 1992-09-08
DE3854604T2 (de) 1996-03-28
AU604542B2 (en) 1990-12-20
CA1327354C (en) 1994-03-01
AU1545688A (en) 1988-10-10

Similar Documents

Publication Publication Date Title
DE3854604D1 (de) Antientzündungsmittel und zusammensetzungen.
FI882742A7 (fi) Hoitavia aineita ja niitä sisältäviä koostumuksia.
FI972286L (fi) Uudella tavalla substituoituja DTPA-johdoksia, niiden metallikomplekseja, kyseisiä komplekseja sisältäviä farmaseuttisia aineita ja niiden käyttö diagnosoinnissa ja terapiassa
DE68912334D1 (de) Immunokonjugate für krebs-diagnose und -therapie.
DE3673000D1 (de) Aether-isonitrile und ihre radiomarkierten komplexe.
FI881061A7 (fi) Hitaasti vapauttavia valmisteita ruoansulatuskanavan ulkopuolisesti annettaviksi ja niiden käyttö.
IT1229195B (it) Derivati xantinici ad attivita' broncodilatatrice e loro applicazioni terapeutiche.
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
FI862882A7 (fi) 1-substituoituja oksindoli-3 -karboksiamideja tulehdusta ja kipua estävinä aineina.
NO900985L (no) Oksiderende flamme og brenner.
DE3875866D1 (de) Sulfonamidolphenyl-derivate und diese enthaltende therapeutische und vorbeugend wirkende mittel gegen arrhythmie.
DK252688D0 (da) Antitumorplatinkomplekser, fremgangsmaade til fremstilling deraf, samt deres terapeutiske anvendelse
ATE81004T1 (de) Laktamimide in der behandlung arzneiresistenter protozoeninjektionen.
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол
DE3867086D1 (de) Benzothiepino(5,4-c)pyridazin-verbindungen und ihre pharmazeutischen wirkungen.
ATE91415T1 (de) Phenoxy- und phenylthio-, amino-substituierte benzocyclo-alkan-derivate bei der behandlung und verhuetung von arzneimittelresistenten protozoen- infektionen.
DE3873167D1 (de) Thiazolidin-4-on-derivate und deren saeure-additionssalze.
DE3674017D1 (de) Oxalursaeure-derivate und pharmazeutisches mittel.
IT1233446B (it) Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
DE3881925D1 (de) Glycerol-derivate und anti-hypertensives mittel.
PT81621B (pt) Processo para a preparacao de derivados da glicerilfosforilcolina possuindo actividade terapeutica e de suas composicoes farmaceuticas
FI883484A7 (fi) Bentsimidatsolijohdannaiset, niiden valmistus ja käyttö terapiassa.
IT8722218A0 (it) Ftalazino derivati ad attivita'farmaceutica.
ATA125688A (de) 1-amino-2-(phenoxypropylamino)-1-cyclobuten-3,4 dionderivate und ihre verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee